Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Breast Neoplasms 3Leukemia, Myeloid, Chronic-Phase 2Leukemia 2Philadelphia Chromosome 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Glioblastoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Imatinib Mesylate 8Dasatinib 4Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2Prednisone 2Daunorubicin 2Cyclophosphamide 2venetoclax 1ponatinib 1olverembatinib 1flumatinib 1bosutinib 1blinatumomab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mercaptopurine 1Interferons 1Inotuzumab Ozogamicin 1Etoposide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Philadelphia Chromosome × bosutinib × Clear all
NCT00261846 2017-07-27

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Pfizer

Phase 2 Completed
571 enrolled 48 charts
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡